Human menopause gonadotropin can treat polycystic ovary syndrome

  Human menopausal gonadotropin is a substance extracted from the urine of menopausal women, containing follicle stimulating hormone and luteinizing hormone. Its role in promoting follicle development is mainly follicle stimulating hormone, which can be used in the treatment of polycystic ovary syndrome.

  Human menopause gonadotropin treatment of polycystic ovary syndrome

  Intramuscular injection of 2 needles (each containing 75 units of follicle stimulating hormone / 75 units of luteinizing hormone) per day should be administered from the second to third day of menstruation. Patients with poor follicular development can be indicated by b-ultrasound after 5-7 days. The dose should be increased to 3 or 4 needles per day. When the follicles reach 18 -- 20mm, gonadotropin 5000 -- 10,000 units can be intramuscular injected to induce ovulation. Treatment should be carried out under the close supervision of ultrasound and blood estradiol.

  The indication of gonadotropin in human menopause

  Amenorrhea patients; The basal body temperature does not rise even if there is ovulation, the application of human menopause gonadotropin can increase the pregnancy rate; Artificial insemination, gamete transplantation, hyperovulation induction during in vitro fertilization.

  Gonadotropin assists gonadotropin releasing hormone in the treatment of human menopause

  A large dose of gonadotropin-releasing hormone-a was injected subcutaneously once A day for 4 weeks, followed by use of menopausal gonadotropin-stimulating follicular development.

  Tips: human gonadotropin during menopause can promote ovulation in patients with polycystic ovary syndrome, so as to achieve the effect of treatment.